The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer’s Disease

被引:0
|
作者
Xianbo Zhuang [1 ]
Jie Lin [2 ]
Yamin Song [3 ]
Ru Ban [1 ]
Xin Zhao [1 ]
Zhangyong Xia [1 ]
Zheng Wang [1 ]
Guifeng Zhang [4 ]
机构
[1] Liaocheng People’s Hospital and Liaocheng Hospital Affiliated to Shandong First Medical University,Department of Neurology
[2] Shandong University,School of Basic Medicine Sciences
[3] Liaocheng People’s Hospital,Department of Joint Laboratory for Translational Medicine Research
[4] Liaocheng People’s Hospital,Department of Neurology
[5] Shandong University,Department of Neurology
[6] the Second People’s Hospital of Liaocheng,Department of Neurosurgery
[7] Liaocheng Traditional Chinese Medicine Hospital,undefined
关键词
Alzheimer’s disease; PANoptosis; Amyloid-beta; Tau protein; Inflammation; Therapeutic strategy;
D O I
10.1007/s12017-024-08815-z
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder, and the vast majority of cases occur in elderly patients. Recently, the accumulation of Aβ and tau proteins has drawn considerable attention in AD research. This review explores the multifaceted interactions between these proteins and their contribution to the pathological landscape of AD, encompassing synaptic dysfunction, neuroinflammation, and PANoptosis. PANoptosis is a collective term for programmed cell death (PCD) modalities that encompass elements of apoptosis, pyroptosis, and necroptosis. The accumulation of Aβ peptides and tau proteins, along with the immune response in brain cells, may trigger PANoptosis, thus advancing the progression of the disease. Recent advancements in molecular imaging and genetics have provided deeper insights into the interactions between Aβ peptides, tau proteins, and the immune response. The review also discusses the role of mitochondrial dysregulation in AD. The exploration of the interplay between neurodegeneration, immune responses, and cell death offers promising avenues for the development of innovative treatments.
引用
收藏
相关论文
共 50 条
  • [41] RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
    Yan, SD
    Chen, X
    Fu, J
    Chen, M
    Zhu, HJ
    Roher, A
    Slattery, T
    Zhao, L
    Nagashima, M
    Morser, J
    Migheli, A
    Nawroth, P
    Stern, D
    Schmidt, AM
    NATURE, 1996, 382 (6593) : 685 - 691
  • [42] Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain
    Wildburger, Norelle C.
    Esparza, Thomas J.
    LeDuc, Richard D.
    Fellers, Ryan T.
    Thomas, Paul M.
    Cairns, Nigel J.
    Kelleher, Neil L.
    Bateman, Randall J.
    Brody, David L.
    SCIENTIFIC REPORTS, 2017, 7
  • [43] Innate immunity and amyloid-beta clearance in Alzheimer's disease
    Fiala, M
    Chiappelli, F
    Graves, MC
    NEUROBIOLOGY OF AGING, 2004, 25 : S533 - S533
  • [44] Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
    Evan Dorey
    Nina Chang
    Qing Yan Liu
    Ze Yang
    Wandong Zhang
    Neuroscience Bulletin, 2014, 30 : 317 - 330
  • [45] Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
    Norelle C. Wildburger
    Thomas J. Esparza
    Richard D. LeDuc
    Ryan T. Fellers
    Paul M. Thomas
    Nigel J. Cairns
    Neil L. Kelleher
    Randall J. Bateman
    David L. Brody
    Scientific Reports, 7
  • [46] Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease
    Dorey, Evan
    Chang, Nina
    Liu, Qing Yan
    Yang, Ze
    Zhang, Wandong
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 317 - 330
  • [47] Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease
    Evan Dorey
    Nina Chang
    Qing Yan Liu
    Ze Yang
    Wandong Zhang
    Neuroscience Bulletin, 2014, 30 (02) : 317 - 330
  • [48] Epigenetic Regulation of Amyloid-beta Metabolism in Alzheimer's Disease
    He, Chuan
    Huang, Zhong-sheng
    Yu, Chao-chao
    Wang, Hai-hua
    Zhou, Hua
    Kong, Li-hong
    CURRENT MEDICAL SCIENCE, 2020, 40 (06): : 1022 - 1030
  • [49] PET amyloid-beta imaging in preclinical Alzheimer's disease
    Vlassenko, Andrei G.
    Benzinger, Tammie L. S.
    Morris, John C.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2012, 1822 (03): : 370 - 379
  • [50] Impaired hepatic amyloid-beta degradation in Alzheimer's disease
    Maarouf, Chera L.
    Walker, Jessica E.
    Sue, Lucia I.
    Dugger, Brittany N.
    Beach, Thomas G.
    Serrano, Geidy E.
    PLOS ONE, 2018, 13 (09):